Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VCE versus VAD for newly diagnosed metastatic childhood renal tumors
NL-OMON54046Phase 3Not yet recruiting
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Apr 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vincristine, actinomycin D, doxorubicin, carboplatin and etoposide in Wilms' tumor and Nephroma, sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoint: Overall metastatic rapid response rate after 6 weeks. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
vincristineactinomycin Ddoxorubicincarboplatinetoposide
03
Conditions
Wilms' tumorNephroma
Beyond the preview
Go deeper on NL-OMON54046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54046.